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Abstract 
Interleukin-1β (IL-1β) and -6 (IL-6) are inflammatory cytokines that are involved in bone resorption under 
pathological conditions. The cytokines are also involved in bone remodeling under physiological conditions. 
Voltage sensitive Ca2+ channels (VSCCs) serve as crucial mediators of membrane excitability and many 
Ca2+-dependent functions such as growth of bone, regulate proliferation, differentiation, enzyme activity and 
gene expression. The effects of IL-1β and -6 on VSCCs in osteoblast cell line (MC3T3-E1) were investigated 
using patch-clamp recording. Our results showed that application of 50 pM-50 nM IL-1β facilitated VSCCs 
current (ICa) carried by Ba2+ (IBa). Application of 50 pM-5 nM IL-6 facilitated IBa. In contrast, 50 nM IL-6 
inhibited IBa in MC3T3-E1 cells. Treatment with MAPK inhibitor, PD98059, attenuated the 5 nM IL-6-induced 
facilitation of IBa. Treatment with STAT3 inhibitor, staffic, attenuated the 50 nM IL-6-induced inhibition of IBa. 
Treatment with PD98059 also attenuated the 50 nM IL-6-induced inhibition of IBa. These results suggest that 5 
nM IL-6 facilitates VDCCs involving MAPK pathways. In addition, 50 nM IL-6 inhibits VDCCs involving 
STAT3 and MAPK pathways in MC3T3-E1 cells. 
Keywords: osteoblasts, Interleukin-1β, Interleukin-6, calcium channels 
1. Introduction 
Interleukin-1β (IL-1β), a potent inflammatory cytokine, is upregulated during inflammation mainly produced by 
activated monocytes and macrophages (Dinarello, 1997; Stylianou et al., 1998). It stimulates bone resorption in 
several cell types, including osteoblasts (Dinarello, 1988). IL-6 is a multifunctional cytokine which has diverse 
effects on bone metabolism. IL-6 has been shown to affect growth and differentiation in osteoblasts (Fang et al., 
1991; Hughes et al., 1992; Ishimi et al., 1990). 
Osteoblasts are known to play a major role in the bone formation. It is well accepted that osteoblasts express 
IL-1β and -6 receptors and therefore it plays an important role in bone remodeling (Blanchard et al., 2009;   
Shen et al., 1990). 
Voltage sensitive Ca2+ channels (VSCCs) serve as crucial mediators of membrane excitability (Miller, 1987) and 
many Ca2+-dependent functions such as growth of bone (Duriez et al., 1993), regulate proliferation (Loza et al., 
1994), differentiation (Wen et al., 2012), enzyme activity (Reuter 1983) and gene expression (Murphy et al., 
1991). It also has been demonstrated that osteoblasts express VSCCs (Duncan et al., 1998; McDonald, 2004). 
Several reports demonstrated that IL-1β and -6 modulated VSCCs in neuronal cells (Ma et al., 2012; Zhou et al., 
2006). However, the mechanism of IL-1β and -6 effects on VSCCs in osteoblasts has been extensively studied, 
but remains unclear and even controversial. 
Consequently, in this study we investigated the effect of IL-1β and -6 on VSCCs in osteoblast cell line 
(MC3T3-E1). 
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2. Materials and Methods 
2.1 Cell Culture 
Murine osteoblastic MC3T3-E1 cells were purchased from Summit Pharmaceuticals International Corporation 
(Tokyo, Japan). Cells were cultured at 37°C in a 5%(v/v) CO2 atmosphere with α-modified minimal essential 
medium (α-MEM; Gibco BRL, Grand Island, NY, U.S.A.). Unless otherwise specified, the medium contained 
10%(v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. Cell culture 
medium was changed every 2-3 days. For patch-clamp experiments, cells were harvested using a 0.05% 
trypsin/0.02% EDTA solution, when cells reached confluence. Cells were plated at very low density in 35 mm 
tissue culture dishes. Prior to recordings, the cells were washed at least three times with Krebs solution of the 
following composition (in mM): 136 NaCl; 5 KCl; 2.5 CaCl2; 0.5 MgCl2; 10.9 glucose; 11.9 NaHCO3 and 1.1 
NaH2PO4. The pH was 7.3-7.4. Cell culture reagents were purchased from Sigma (Tokyo, Japan). Our recordings 
were performed on 10-30 μm in diameter, since they were well suited for patch clamp recordings. 
2.2 Whole-Cell Patch-Clamp Recordings 
Voltage-clamp recordings were conducted using the whole-cell configuration of the patch-clamp technique 
(Hamill et al., 1981). Fabricated recording pipettes (2-3 MΩ) were filled with the internal solution of the 
following composition (in mM): 150 CsCl; 5 EGTA; 10 D-glucose and 10 HEPES. The pH was adjusted to 7.3 
with CsOH. After the formation of a giga seal, in order to record VSCCs current (ICa) carried by Ba2+ (IBa), the 
extracellular solution was replaced from Krebs solution to a solution containing the following (in mM): 115 
BaCl2 and 20 HEPES. The pH was adjusted to 7.4 with tetraethylammonium hydroxide. Command voltage 
protocols were generated with a computer software pCLAMP version 10 (Axon Instruments, Union City, CA, 
U.S.A.) and transformed to an analogue signal using a DigiData1440A interface (Axon Instruments, Union City, 
CA, U.S.A.). The command pulses were applied to cells through an L/M-EPC7 amplifier (HEKA Elektronik, 
Lambrecht, Germany). The currents were recorded with the amplifier and a computer software pCLAMP10 
acquisition system. Access resistance (< 15 MΩ) was determined by transient responses to voltage commands. 
L-1β and -6 were applied by perfusion pressure ejection from perfusion tubes with a tip diameter of 1 mm placed 
within 10 mm of the cell surface. Although the concentration of IL-1β and -6 actually seen by the cell is certainly 
lower than that contained in the stock solution, we applied the IL-1β and -6 using same perfusion system. L-1β 
and -6 were applied by perfusion pressure ejection from perfusion tubes with a tip diameter of 1 mm placed 
within 10 mm of the cell surface.  
2.3 Chemicals 
IL-1β, IL-6 and PD98059 were purchased from Sigma (Tokyo, Japan). SQ22536 was purchased from Biomol 
Research Laboratories (Plymouth, PA, U.S.A.) 
2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide (GF109203X) was purchased from 
Calbiochem (La Jolla, CA, U.S.A.). Staffic was purchased from Tocris (Bristol, U.K.). All drugs except 
GF109203X and staffic were dissolved in distilled water. GF109203X and Stattic were dissolved in DMSO. All 
drugs were diluted to the desired final concentration in the external solution just before use. The final 
concentration of DMSO was ＜ 0.01%, which had no effect on the IBa. 
2.4 Statistical Analysis 
All date analyses were performed using the pCLAMP10 acquisition system. Values in text and figures are 
expressed as mean ± S.E.M. Statistical analysis was done using Student’s t test for comparisons between pairs of 
groups and one-way analysis of variance (ANOVA) followed by Dunnett’s test. Probability (p) values of less 
than 0.05 were considered significant. Modulation of IBa was calculated with the following formula: 
Modulation of IBa (%) = After Application peak current / Before Application peak current 
 
Table 1. Statistical mean ± S.E.M. at each concentration levels 
 IL-1β n IL-6 n 
50 pM 22.8±4.0 5 15.8 ± 2.7 10 
500 pM 21.8 ± 2.0 6 23.0 ± 4.5 7 
5 nM 34.1 ± 3.9 6 35.6 ± 4.0 8 
50 nM 56.7 ± 5.2 3 -21.4 ± 2.5 3 
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Table 2. Statistical mean ± S.E.M. for IL-6 treated with each inhibitors. 
 IL-1β n IL-6 n 
Control 35.6 ± 4.0 8 -21.4 ± 2.5 4 
SQ22536 30.0 ± 3.6 4 -21.4 ± 1.3 5 
GF109203 36.9 ± 6.4 4 -22.6 ± 1.4 5 
Staffic 35.2 ± 4.8 4 -3.5 ± 0.6 5 
PD98059 7.5 ± 1.1 4 -4.0 ± 0.9 5 
 
3. Results 
3.1 IL-1β Facilitated IBa 
Figure 1a and b shows that, in the presence of high external Ba2+, 5 nM IL-1β facilitated IBa as shown with raw 
current traces obtained at +10 mV from ―80 mV in the absence and presence of IL-1β. IBa was evoked every 5 s 
with a 100 ms depolarizing voltage step to ―10 mV from a holding potential of ―80 mV. As shown in Figure 
1a, application of 5 nM IL-1β facilitated IBa from ―161 pA to ―225 pA (39.7% facilitation) in this cell. 
To investigate the voltage dependency of facilitation of IBa by IL-1β, we analyzed the current-voltage relations in 
the absence and presence of IL-1β. The current-voltage relations measured before and during application of 
IL-1β are shown in Figure 1c. From a holding potential of ―80 mV, IBa was activated with a peak current 
amplitude at 0 mV. IL-1β did not alter the current-voltage relationship. These results suggest that 5 nM IL-1β 
facilitated IBa in MC3T3-E1 cells. 
 
 
Figure 1. (a) Typical superimposed IBa traces according to the time course graph B. IBa was evoked from a holding 
potential of －80 mV by a 100 msec voltage step to －10 mV at 5 sec intervals. (b) Typical time course of 5 nM 
IL-1β-induced facilitation of IBa. IL-1β (5 nM) was bath-applied during the times indicated by the filled bar. (c) 
Current-voltage relationship of IBa evoked by a series of voltage steps from a holding potential of －80 mV to test 
potentials between －80 and ＋40 mV in ＋10 mV increments in the absence (opened circles) and presence 
(filled circles) of 5 nM IL-1β 
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3.2 IL-6 Facilitated IBa 
Figure 2a and b shows that 5 nM IL-6 facilitated IBa as shown with raw current traces obtained at +10 mV from 
―80 mV in the absence and presence of IL-6. IBa was evoked every 5 s with a 100 ms depolarizing voltage step 
to ―10 mV from a holding potential of ―80 mV. As shown in Figure 2A, application of 5 nM IL-6 facilitated 
IBa from ―75 pA to ―103 pA (37.3% facilitation) in this cell. 
To investigate the voltage dependency of facilitation of IBa by 5 nM IL-6, we analyzed the current-voltage 
relations in the absence and presence of 5 nM IL-6. The current-voltage relations measured before and during 
application of 5 nM IL-6 are shown in Figure 2c. From a holding potential of ―80 mV, IBa was activated with a 
peak current amplitude at 20 mV. IL-6 did not alter the current-voltage relationship. These results suggest that 5 
nM IL-6 facilitated IBa in MC3T3-E1 cells. 
 
 
Figure 2. (a) Typical superimposed IBa traces according to the time course graph B. IBa was evoked from a 
holding potential of －80 mV by a 100 msec voltage step to －10 mV at 5 sec intervals. (b) Typical time course 
of 5 nM IL-6-induced facilitation of IBa. IL-6 (5 nM) was bath-applied during the times indicated by the filled bar. 
(c) Current-voltage relationship of IBa evoked by a series of voltage steps from a holding potential of －80 mV 
to test potentials between －80 and ＋40 mV in ＋10 mV increments in the absence (opened circles) and 
presence (filled circles) of 5 nM IL-6 
 
3.3 IL-6 Inhibited IBa 
In addition to facilitation, IL-6-induced inhibition of IBa could be observed. Figure 3a and b shows that 50 nM 
IL-6 inhibited IBa as shown with raw current traces obtained at +10 mV from ―80 mV in the absence and 
presence of IL-6. IBa was evoked every 5 s with a 100 ms depolarizing voltage step to ―10 mV from a holding 
potential of ―80 mV. As shown in Figure 3a, application of 50 nM IL-6 inhibited IBa from ―328 pA to ―236 
pA (28.0% inhibition) in this cell. 
To investigate the voltage dependency of facilitation of IBa by 50 nM IL-6, we analyzed the current-voltage 
relations in the absence and presence of 50 nM IL-6. The current-voltage relations measured before and during 
application of 50 nM IL-6 are shown in Figure 3c. From a holding potential of ―80 mV, IBa was activated with a 
peak current amplitude at 20 mV. IL-6 did not alter the current-voltage relationship. These results suggest that 50 
nM IL-6 inhibited IBa in MC3T3-E1 cells. 
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Figure 3. (a) Typical superimposed IBa traces according to the time course graph B. IBa was evoked from a 
holding potential of －80 mV by a 100 msec voltage step to －10 mV at 5 sec intervals. (b) Typical time course 
of 50 nM IL-6-induced inhibition of IBa. IL-6 (50 nM) was bath-applied during the times indicated by the filled 
bar. (c) Current-voltage relationship of IBa evoked by a series of voltage steps from a holding potential of －80 
mV to test potentials between －80 and ＋40 mV in ＋10 mV increments in the absence (opened circles) and 
presence (filled circles) of 50 nM IL-6 
 
 
Figure 4. (a) Histogram demonstrating the degree of IBa modulation by 50 pM-50 nM IL-1β. (b) Histogram 
demonstrating the degree of IBa modulation by 50 pM-50 nM IL-6 
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Figure 5. (a) Summary of IL-6-induced facilitation of IBa under various conditions. Histogram demonstrating the 
degree of IBa facilitation by 5 nM IL-6 in control (untreated cells), after SQ22536 (an AC inhibitor), after 
GF109203 (a PKC inhibitor), after staffic (a STAT3 inhibitor), and PD98059 (a MAPK inhibitor). (b) Summary 
of IL-6-induced inhibition of IBa under various conditions. Histogram demonstrating the degree of IBa inhibition 
by 50 nM IL-6 in control (untreated cells), after SQ22536 (an AC inhibitor), after GF109203 (a PKC inhibitor), 
after staffic (a STAT3 inhibitor), and PD98059 (a MAPK inhibitor). *＜0.05 compared with control 
 
3.4 IL-1β and -6 Modulated IBa Depends On Concentration 
The concentration-response relationship in the IL-1β and -6-induced modulation of IBa is shown in Figure 4a and 
b, respectively.  
Application of 50 pM-50 nM IL-1β facilitated IBa. To generate a concentration-response curve, IL concentrations 
were applied randomly, and each MC3T3-E1 cells were exposed to only a single concentration. Figure 4a shows 
that progressive voltage-dependent facilitations in IL-1β concentrations resulted in a progressively greater 
facilitation of IBa. 
In addition, application of 50 pM-5 nM IL-6 facilitated IBa. In contrast to above results, 50 nM IL-6 inhibited IBa 
in MC3T3-E1 cells. 
3.5 Characterization of Second Messengers in 5 nM IL-6-Induced Facilitation of IBa  
To evaluate the possible contribution of adenylate cyclase (AC) to the IL-6-induced facilitation of IBa, the effects 
of IL-6 on IBa in cells treated with SQ22536 (an AC inhibitor) were investigated. Treatment with SQ22536 (10 
μM for 30 min) did not attenuate the IL-6-induced facilitation of IBa. 
To evaluate the possible contribution of protein kinase C (PKC) to the IL-6-induced facilitation of IBa, the effects 
of IL-6 on IBa in cells treated with GF109203X (a selective PKC inhibitor) were investigated. Treatment with 
GF109203X (10 μM for 30 min) did not attenuate the IL-6-induced facilitation of IBa. 
To evaluate the possible contribution of STAT3 to the IL-6-induced facilitation of IBa, the effects of IL-6 on IBa 
in cells treated with staffic (a selective signal transducers and activators of transcription 3, STAT3, inhibitor) 
were investigated. Treatment with staffic (20 μM for 2 min) did not attenuate the IL-6-induced facilitation of IBa. 
To evaluate the possible contribution of MAPK to the IL-6-induced facilitation of IBa, the effects of IL-6 on IBa 
in cells treated with PD98059 (a selective MAPK inhibitor) were investigated. Treatment with PD98059 (10 μM 
for 2 min) attenuated the IL-6-induced facilitation of IBa. 
These results suggest that IL-6 facilitates VDCCs involving MAPK pathways in MC3T3-E1 cells. 
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3.6 Characterization of Second Messengers in 50 nM IL-6-Induced Inhibition of IBa  
To evaluate the possible contribution of AC to the IL-6-induced inhibition of IBa, the effects of IL-6 on IBa in 
cells treated with SQ22536 (an AC inhibitor) were investigated. Treatment with SQ22536 (10 μM for 30 min) 
did not attenuate the IL-6-induced inhibition of IBa. 
To evaluate the possible contribution of protein kinase C (PKC) to the IL-6-induced inhibition of IBa, the effects 
of IL-6 on IBa in cells treated with GF109203X (a selective PKC inhibitor) were investigated. Treatment with 
GF109203X (10 μM for 30 min) did not attenuate the IL-6-induced inhibition of IBa. 
To evaluate the possible contribution of STAT3 to the IL-6-induced inhibition of IBa, the effects of IL-6 on IBa in 
cells treated with staffic (a selective STAT3 inhibitor) were investigated. Treatment with staffic (20 μM for 2 
min) attenuated the IL-6-induced inhibition of IBa. 
To evaluate the possible contribution of MAPK to the IL-6-induced inhibition of IBa, the effects of IL-6 on IBa in 
cells treated with PD98059 (a selective MAPK inhibitor) were investigated. Treatment with PD98059 (10 μM 
for 2 min) attenuated the IL-6-induced inhibition of IBa. 
These results suggest that IL-6 inhibits VDCCs involving STAT3 and MAPK pathways in MC3T3-E1 cells. 
4. Discussion 
The present study investigated the effects of IL-1β and -6 on IBa in MC3T3-E1 cells. Application of 50 pM-50 nM 
IL-1β facilitated IBa. Application of 50 pM-5 nM IL-6 facilitated IBa involving MAPK pathways. In contrast, 50 nM 
IL-6 inhibited IBa involving STAT3 and MAPK pathways in MC3T3-E1 cells. In this study, we used 50 pM-50 nM 
IL-1β and IL-6 to modulate IBa. These IL concentrations are quite high. In normal state, serum IL-1β concentration 
is 0.9 pg/ml approximately (Chang et al., 2013). In the electrophysiological study and the immunocytochemistry 
study, however, several study demonstrated that high concentration, i.e. 0.57 nM and 4.5 nM, of IL was used to 
modulate ion channel activity and protein expression in single neuron (Zhou et al., 2006; Islam et al., 2009). IL-1β 
and -6 were applied by perfusion pressure ejection from perfusion tubes with a tip diameter of 1 mm placed within 
10 mm of the cell surface. Although the concentration of IL-1β and -6 actually seen by the cell is certainly lower 
than that contained in the stock solution, we applied the IL-1β and -6 using same perfusion system. We also 
observed that IBa were recovered to values of peak IBa after IL wash out using time course graph (Figures. 1b, 2b 
and 3b). Therefore, it can be considered that 50 pM-50 nM IL-1β and IL-6 had no effect on the IBa. 
In osteoblastic cells, several studies demonstrated that hormones modulated VSCCs, included in parathyroid 
hormone (PTH) (Green et al., 1991; Li et al., 1997; Yamaguchi et al., 1987), bradykinin (Tokuda et al., 1994), 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (Bergh et al., 2006; Uchida et al., 2012; Zanello et al., 2006) and 
phalloidin, a stabilizer of actin filaments (Li et al., 2011). To our knowledge, the data presented here demonstrate 
for the first time that IL-1β and -6 modulates VSCCs in osteoblasts. In contrast to our results, Green et al. 
reported that IL-6 did not alter basal intracellular Ca2+ concentration ([Ca2+]i) but inhibited Ca2+ transient 
induced by PTH, prostaglandin E2 and endothelin-1 in osteoblast (Green et al., 1994). 
In this study, we have shown that 50 pM-50 nM IL-1β facilitated IBa. It has been demonstrated that local 
treatment with IL-1β (0.5 ng/h) for 72 h resulted in increased osteoblasts concentration (Olmedo et al., 1999). 
Furthermore, reports of IL-1β promoting osteoblast proliferation during acute bone repair (Lange et al., 2009) 
and inducing differentiation of human mesenchymal stem cells into osteoblasts (Sonomoto et al., 2012). 
Increased DNA synthesis in response to IL-1β in vitro has been observed in osteoblast (Evans et al., 1989) and 
especially MC3T3-E1 cells (Ikeda et al., 1998). In contrast, however, it has been reported that IL-1β inhibits the 
stimulation of osteocalcin synthesis and has no influence on proliferation (Taichman et al., 1992). IL-1β also 
increases both osteoprotegerin protein release and mRNA levels (Hofbauer et al., 1998; Hofbauer et al., 1999). 
Recent study demonstrated that treatment with IL-1β resulted in biphasic effects on osteoblast differentiation. 
Short-term exposure (2 days) to IL-1β early in culture induces differentiation. Longer term exposure (6 days) to 
IL-1β inhibits osteoblast differentiation (Bellido et al., 1997). 
In this study, we have shown that 50 pM-5 nM IL-6 facilitated IBa involving MAPK pathways. In contrast, 50 nM 
IL-6 inhibited IBa involving STAT3 and MAPK pathways. What is the physiological relevance of IL-6-induced dual 
modulation of VSCCs, i.e. both facilitation and inhibition? Several studies indicated that IL-6 enhanced in vitro 
differentiation on osteoblasts (Bellido et al., 1997; Bellido et al., 1998; Franchimont et al., 2005; Itoh et al., 2006; 
Liu et al., 2006; Wong et al., 2003). In contrast to above reports, other studies have shown an inhibitory effect of 
IL-6 on bone formation (Malaval et al., 2001; Malaval et al., 2005). It can be considered that such dual effects are 
depends on IL-6 receptor's intracellular signals transduction mechanisms. There are three major MAPK subgroups 
identified, including the extracellular signal-regulated kinases (ERK1/2), p38 MAPK and c-jun-NH2-terminal 
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kinases (JNKs). The signal transduction induced by IL-6 is mediated by homo- or heterodimerization of the gp130 
receptor, subsequent activation of JAK, and phosphorylation of STAT (Heinrich et al., 2003). It has been 
demonstrated that activation of STAT3 is necessary for osteoblast differentiation and bone formation induced by 
IL-6 (Itoh et al., 2006). On the other hand, PKCδ and ERK1/2 are implicated in IL-6's inhibitory effect on bone 
formation (Chipoy et al., 2004). STAT3 plays multiple roles depending on the context or condition of cells. In some 
conditions, STAT3 is involved in growth arrest and differentiation, and even in cell death (Nakajima et al., 1996; 
Hirano et al., 1997; Hirano et al., 2000). In other conditions, STAT3 is involved in proliferation and cell survival 
(Hirano et al., 1997; Hirano et al., 2000). It is also possible that these dual effects depend on the conditions or 
differentiation stage of the osteoblast. IL-6 would stimulate the first stages of differentiation but on more mature 
cells, they would prevent further stimulation (Malaval et al., 2001; Malaval et al., 2005). Interestingly, VSCCs 
serve as growth of bone, regulate proliferation and differentiation, as mentioned above. 
References 
Bellido, T., Borba, V. Z., Roberson, P., & Manolagas, S. C. (1997). Activation of the Janus kinase/STAT (signal 
transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines 
promotes osteoblast differentiation. Endocrinology, 138, 3666-3676. 
Bellido, T., O’Brien, C. A., Roberson, P. K., & Manolagas, S. C. (1998). Transcriptional activation of the p21 
(WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and 
anti-apoptotic effects on human osteoblastic cells. J Biol Chem, 273, 21137-21144. http://dx.doi.org/10. 
1074/jbc.273.33.21137 
Bergh, J. J., Shao, Y., Puente, E., Duncan, R. L., & Farach-carson, M. C. (2006). Osteoblast Ca2+ permeability 
and voltage-sensitive Ca2+ channel expression is temporally regulated by 1,25-dihydroxyvitamin D3. Am J 
Physiol, 290, C822-C831. http://dx.doi.org/10.1152/ajpcell.00403.2005 
Blanchard, F., Duplomb, L., Baud’huin, M., & Brounais, B. (2009). The dual role of IL-6-type cytokines on 
bone remodeling and bone tumors. Cytokine Growth Factor Rev, 20, 19-28.  
Chang, J. S., Chang, C. C., Chien, E. Y., Lin, S. S., Cheng-Shiuan, T., Bai, C. H., & Chao, K. C. (2013). 
Association between interleukin 1β and interleukin 10 concentrations: a cross-sectional study in young 
adolescents in Taiwan. BMC pediatrics, 13(1), 123. http://dx.doi.org/10.1186/1471-2431-13-123 
Chipoy, C., Berreur, M., Couillaud, S., Pradal, G., Vallette, F., Colombeix, C., … Blanchard, F. (2004). 
Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in 
osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res, 19, 1850-1861. http://dx.doi.org/10. 
1359/JBMR.040817 
Dinarello, C. A. (1988). Biology of interleukin 1. FASEB J, 2, 108-115. 
Dinarello, C. A. (1997). Interleukin-1. Cytokine Growth Factor Rev, 8, 253-265. http://dx.doi.org/10.1016/S1359 
-6101(97)00023-3 
Duncan, R. L., Akanbi, K. A., & Farach-Carson, M. C. (1998). Calcium signals and calcium channels in 
osteoblastic cells. Sem Nephrol, 18, 178-190. 
Duriez, J., Flautre, B., Blary, M. C., & Hardouin, P. (1993). Effects of the calcium channel blocker nifedipine on 
epiphyseal growth plate and bone turnover: a study in rabbit. Calcif Tissue Int, 52, 120-124. 
http://dx.doi.org/10.1007/BF00308320 
Evans, D. B, Bunning, R. A., Van Damme, J., & Russell, R. G. (1989). Natural human IL-1 beta exhibits 
regulatory actions on human bone-derived cells in vitro. Biochem Biophys Res Commun, 159, 1242-1248. 
http://dx.doi.org/10.1016/0006-291X(89)92243-2 
Fang, M. A., & Hahn, T. J. (1991). Effects of interleukin-6 on cellular function in UMR-106-01osteoblast like 
cells. J Bone Miner Res, 6, 133-139. http://dx.doi.org/10.1002/jbmr.5650060206 
Franchimont, N., Wertz, S., & Malaise, M. (2005). Interleukin-6: an osteotropic factor influencing bone 
formation? Bone, 37, 601-606. http://dx.doi.org/10.1016/j.bone.2005.06.002 
Green, J., Kleeman, C. R., Schotland, S., & Chaimovitz, C. (1991). Acute phosphate depletion dissociates 
hormonal stimulated second messengers in osteoblast-like cells. Endocrinology, 129, 848-858. 
http://dx.doi.org/10.1210/endo-129-2-848 
Green, J., Schotland, S., Sella, Z., & Kleeman, C. R. (1994). Interleukin-6 attenuates agonist-mediated calcium 
mobilization in murine osteoblastic cells. J Clin Invest, 93, 2340-2350. http://dx.doi.org/10.1172/JCI117239 
www.ccsenet.org/ijb International Journal of Biology Vol. 7, No. 2; 2015 
76 
Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981). Improved patch-clamp techniques 
for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch, 391, 
85-100. http://dx.doi.org/10.1007/BF00656997 
Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Muller-Newen, G., & Schaper, F. (2003). Principles 
of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J, 374, 1-20. http://dx.doi.org/10. 
1042/BJ20030407 
Hirano, T., Ishihara, K., & Hibi, M. (2000). Role of STAT3 in mediating the cell growth, differentiation and 
survival signals related through the IL-6 family of cytokine receptors. Oncogene, 19, 2548-2556. 
http://dx.doi.org/10.1038/sj.onc.1203551 
Hirano, T., Nakajima, K., & Hibi, M. (1997). Signaling mechanisms through gp130; a model of the cytokine 
system. Cytokine Growth Factor Rev, 8, 241-252. http://dx.doi.org/10.1016/S1359-6101(98)80005-1 
Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1998). Osteoprotegerin production 
by human osteoblast lineage cells is stimulated by vitamin D. bone morphogenetic protein-2, and cytokines. 
Biochem Biophys Res Commun, 250, 776-781. http://dx.doi.org/10.1006/bbrc.1998.9394 
Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1999). 
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand 
gene expression in human osteoblastic cells. Bone, 25, 255-259. http://dx.doi.org/10.1016/S8756-3282 
(99)00162-3 
Hughes, F. J., & Howells, G. L. (1993). Interleukin-6 inhibits bone formation in vitro. Bone Miner, 21, 21-28. 
http://dx.doi.org/10.1016/S0169-6009(08)80117-1 
Ikeda, E., Kusaka, M., Hakeda, Y., Yokota, K., Kumegawa, M., & Yamamoto, S. (1998). Effect of interleukin 1 beta 
on osteoblastic clone MC3T3-E1 cells. Calcif Tiss Int, 43, 162-166. http://dx.doi.org/10.1007/BF02571314 
Ishimi, Y., Miyaura, C., Jin, C. H., Akasu, T., Abe, E., Nakamura, Y., … Suda, T. (1990). IL-6 is produced by 
osteoblastsand induces bone resorption. J Immunol, 145, 3297-3303. 
Islam, O., Gong, X., Rose-John, S., & Heese, K. (2009). Interleukin-6 and neural stem cells: more than 
gliogenesis. Mol Biol Cell, 20, 188-99. http://dx.doi.org/10.1091/mbc.E08-05-0463 
Itoh, S., Udagawa, N., Takahashi, N., Yoshitake, F., Narita, H., Ebisu, S., & Ishihara, K. (2006). A critical role 
for interleukin-6 family-mediated Stat3 activation in osteoblast differentation and bone formation. Bone, 39, 
505-512. http://dx.doi.org/10.1016/j.bone.2006.02.074 
Lange, J., Sapozhnikova, A., Lu, C., Hu, D., Li, X., Miclau, T. 3rd, & Marcucio, R. S. (2010). Action of 
IL-1beta during fracture healing. J Orthop Res., 28, 778-84. 
Li, F., Wang, W., Gu, M., Gyoneva, S., Zhang, J., Huang, S., … Zhang, X. (2011). L-type calcium channel 
activity in osteoblast cells is regulated by the actin cytoskeleton independent of protein trafficking. J Bone 
Miner Metab, 29, 515-525. http://dx.doi.org/10.1007/s00774-010-0252-6 
Li, W., Duncan, R. L., Karin, N. J., & Farach-Carson, M. C. (1997). 1,25 (OH)2D3 enhances PTH-induced Ca2+ 
transients in preosteoblasts by activating L-type Ca2+ channels. Am J Physiol, 273, E599-E605. 
Lin, F. H., Chang, J. B., McGuire, M. H., Yee, J. A., & Brigman, B. E. (2010). Biphasic effects of Interleukin-1β 
on osteoblast differentiation in vitro. J Orthop Res, 28, 958-964. 
Liu, X. H., Kirschenbaum, A., Yao, S., & Levine, A. C. (2006). The role of the interleukin-6/gp130 signaling 
pathway in bone metabolism. Vitam Horm, 74, 341-355. http://dx.doi.org/10.1016/S0083-6729(06)74014-6 
Loza, J., Stephan, E., Dolce, C., Dziak, R., & Simasko, S. (1994). Calcium currents in osteoblastic cells: 
dependence upon cellular growth stage. Calcif Tissue Int, 55, 128-133. http://dx.doi.org/10.1007/BF00297188 
Ma, S. H., Li, B., Huang, H. W., Peng, Y. P., & Qiu, Y. H. (2012). Interleukin-6 inhibits L-type calcium channel 
activity of cultured cerebellar granule neurons. J Physiol Sci, 62, 385-392. http://dx.doi.org/10.1007/s12576 
-012-0215-x 
Malaval, L., & Aubin, J. E. (2001). Biphasic effects of leukemia inhibitory factor on osteoblastic differentiation. 
J Cell Biochem, 81, 63-70. http://dx.doi.org/10.1002/jcb.1086 
Malaval, L., Liu, F., Vernallis, A. B., & Aubin, J. E. (2005). GP130/OSMR is the only LIF/IL-6 family receptor 
complex to promote osteoblast differentiation of calvaria progenitors. J Cell Physiol, 204, 585-593. 
http://dx.doi.org/10.1002/jcp.20312 
www.ccsenet.org/ijb International Journal of Biology Vol. 7, No. 2; 2015 
77 
McDonald, F. (2004). Ion channels in osteoblasts: A story of two intracellular organelles. Surg J R Coll Surg 
Edinb Irel, 2, 63-69. 
Miller, R. J. (1987). Multiple calcium channels and neuronal function. Science, 235, 46-52. http://dx.doi.org/10. 
1126/science.2432656 
Murphy, T. H., Worley, P. H., & Baraban, J. M. (1991). L-type voltage-sensitive calcium channels mediate 
synaptic activation of immediate early genes. Neuron, 7, 625-635. http://dx.doi.org/10.1016/0896-6273 
(91)90375-A 
Nakajima, K., Yamanaka, Y., Nakae, K., Kojima, H., Ichiba, M., Kiuchi, N., … Hirano, T. (1996). A central role 
for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J, 15, 
3651-3658. 
Olmedo, M. L., Landry, P. S., Sadasivan, K. K., Albright, J. A., Meek, W. D., Routh, R., & Marino, A. A. 
(1999). Regulation of osteoblast levels during bone healing. J Orthop Trauma, 13, 356-362. 
http://dx.doi.org/10.1097/00005131-199906000-00006 
Reuter, H. (1983). Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature, 301, 569-574. 
http://dx.doi.org/10.1038/301569a0 
Shen, V., Cheng, S-L., Kohler, N. G., & Peck, W. A. (1990). Characterization and hormonal modulation of IL-1 
binding in neonatal mouse osteoblast like cells. J Bone Miner Res, 5, 507-515. http://dx.doi.org/10.1002/ 
jbmr.5650050513 
Sonomoto, K., Yamaoka, K., Oshita, K., Fukuyo, S., Zhang, X., Nakano, K., … Tanaka, Y. (2012). 
Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the 
Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway. Arthritis Rheum, 64, 3355-63. 
http://dx.doi.org/10.1002/art.34555 
Stylianou, E., & Saklatvala, J. (1998). Interleukin-1. Int J Biochem Cell Biol, 30, 1075-1079. 
http://dx.doi.org/10.1016/S1357-2725(98)00081-8 
Taichman, R. S., & Hauschka, P. V. (1992). Effects of interleukin-1 beta and tumor necrosis factor-alpha on 
osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro. Inflammation, 16, 
587-601. http://dx.doi.org/10.1007/BF00919342 
Tokuda, H., Kotoyori, J., Oiso, Y., & Kozawa, O. (1994). Intracellular signaling mechanism of bradykinin in 
osteoblast-like cells: comparison with prostaglandin E2. Endocrinol J, 4, 189-195. 
Uchida, Y., Endoh, T., Tazaki, M., & Sueishi, K. (2012). Chronic bradykinin treatment alters 
1α,25-dihydroxyvitamin D3-induced calcium current modulation in pre-osteoblasts. Cell Calcium, 51, 
383-392. http://dx.doi.org/10.1016/j.ceca.2011.12.014 
Wen, L., Wang, Y., Wang, H., Kong, L., Zhang, L., Chen, X., & Ding, Y. (2012). L-type calcium channels play 
a crucial role in the proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells. 
Biochem Biophys Res Commun, 424, 439-445. http://dx.doi.org/10.1016/j.bbrc.2012.06.128 
Wong, P. K., Campbell, I. K., Egan, P. J., Ernst, M., & Wicks, I. P. (2003). The role of the interleukin-6 family 
of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum, 48, 1177-1189. 
http://dx.doi.org/10. 1002/art.10943 
Yamaguchi, D. T., Hahn, T. J., Iida-Klein, A., Kleeman, C. R., & Muallem, S. (1987). Parathyroid 
hormone-activated calcium channels in an osteoblast-like clonal osteosarcoma cell line. cAMP-dependent 
and cAMP-independent calcium channels. J Biol Chem, 262, 7711-7718. 
Zanello, L. P., & Norman, A. (2006). 1α,25(OH)2 vitamin D3 actions on ion channels in osteoblasts. Steroids, 
71, 291-297. http://dx.doi.org/10.1016/j.steroids.2005.09.012 
Zhou, C., Ye, H. H., Wang, S. Q., & Chai, Z. (2006). Interleukin-1β regulation of N-type Ca2+ channels in 
cortical neurons. Neurosci Lett, 403, 181-185. http://dx.doi.org/10.1016/j.neulet.2006.04.043 
 
Copyrights 
Copyright for this article is retained by the author(s), with first publication rights granted to the journal. 
This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution 
license (http://creativecommons.org/licenses/by/3.0/). 
